Trial Profile
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort Turbuhaler, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Budesonide/formoterol (Primary) ; Budesonide; Formoterol
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics; Registrational; Therapeutic Use
- Acronyms TELOS
- Sponsors AstraZeneca AB; Pearl Therapeutics
- 16 Sep 2018 Primary endpoint has been met. (Change from baseline in FEV1 AUC 0-4), according to an AstraZeneca media release.
- 16 Sep 2018 According to an AstraZeneca media release, data from the study were presented at the European Respiratory Society (ERS) International Congress 2018 and published in the European Respiratory Journal.
- 16 Sep 2018 Results presented in an AstraZeneca media release.